Pelthos Therapeutics
PTHS
5 hedge funds and large institutions have $59.6K invested in Pelthos Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.24% less ownership
Funds ownership: 0.38% → 0.15% (-0.24%)
79% less capital invested
Capital invested by funds: $290K → $59.6K (-$231K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$46K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$25.4K |
| 3 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$10.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$244 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$265K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$24.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$246 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APP
1
Avantax Planning Partners
Dubuque,
Iowa
| $33.5K | +$46K | +4,721 | New |
|
|
TSS
2
Two Sigma Securities
New York
| $18.5K | +$25.4K | +2,606 | New |
|
|
3
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| $7.38K | +$10.1K | +1,040 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $184 | +$244 | +25 | +2,500% |
|
5
Bank of America
Charlotte,
North Carolina
| $8 | – | – | – |
|
|
AFM
6
Anson Funds Management
Dallas,
Texas
| – | -$265K | -20,103 | Closed |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$24.7K | -1,871 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$246 | -19 | Closed |
|
PTHS Hedge Fund Activity: Q3 2024 in Review
5 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q3 2024, worth a combined $59.6K — down 79% from $290K a quarter earlier.
Fund positioning in PTHS was balanced in Q3 2024: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Avantax Planning Partners, opening a new position worth an estimated $46K. The largest seller was Anson Funds Management, exiting entirely with an estimated $265K sold.
- 5 institutional investors held Pelthos Therapeutics (PTHS) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $59.6K of Pelthos Therapeutics stock for Q3 2024, down 79% quarter-over-quarter.
- 3 funds opened new Pelthos Therapeutics positions in Q3 2024 and 3 closed out, a net change of 0 holders.
- The largest Pelthos Therapeutics buyer in Q3 2024 was Avantax Planning Partners, an estimated $46K added.
- The largest Pelthos Therapeutics seller in Q3 2024 was Anson Funds Management, an estimated $265K sold.
Based on aggregated 13F filings for Q3 2024.